22 recruiting, 8 not yet recruiting, 4 active not recruiting, 2 terminated. 21 Phase 2, 14 Phase 1, 8 Phase 3.
Follow XL092: new trials by email Literature Review of XL092 trials Research Report on XL092
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer Cemiplimab, Zanzalintinib - Anaplastic Thyroid Cancer | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 12 | 2027-01-31 | 2026-10-14 |
| Zanzalintinib in Unresectable and Progressive MPGGs Zanzalintinib - Pheochromocytoma, Paraganglioma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 14 | 2027-01-09 | 2026-07-20 |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma Zanzalintinib - Metastatic Olfactory Neuroblastoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 16 | 2026-10-01 | 2026-10-05 |
| Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors Zanzalintinib - Cancer, Pediatric Cancer | Phase 1 | Not yet recruiting | Exelixis | 18 | 2026-09-30 | 2026-08-19 |
| H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) XL092, Pembrolizumab - Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 26 | 2026-09-01 | 2026-08-31 |
| Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Zanzalintinib - mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 2 | Not yet recruiting | Stuthi Perimbeti | 30 | 2026-09-01 | 2026-06-03 |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-08-25 | 2026-09-21 |
| Zanzalintinib in Men With Aggressive Variant Prostate Cancer Zanzalintinib - Aggressive Variant Prostate Carcinoma | Phase 2 | Recruiting | Deepak Kilari | 30 | 2026-08-19 | 2026-08-28 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma Zanzalintinib - Meningioma | Phase 2 | Recruiting | Exelixis | 100 | 2026-05-21 | 2026-10-28 |
| A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) Belzutifan, Zanzalintinib, Placebo - Carcinoma, Renal Cell | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 758 | 2026-04-09 | 2026-10-29 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Hepatocellular Carcinoma, Cirrhosis | Phase 1 / Phase 2 | Recruiting | Devalingam Mahalingam | 59 | 2026-03-30 | 2026-10-23 |
| Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC XL092, Nivolumab - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Karie Runcie | 70 | 2026-03-13 | 2026-09-22 |
| Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma Zanzalintinib, Ipilimumab, Nivolumab - Metastatic Soft-tissue Sarcoma | Phase 1 | Suspended | Washington University School of Medicine | 18 | 2026-01-05 | 2026-09-04 |
| A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) Zanzalintinib - Bone Sarcomas | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 70 | 2025-12-05 | 2026-09-25 |
| A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) Belzutifan, Zanzalintinib, Cabozantinib - Renal Cell Carcinoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 904 | 2025-11-26 | 2026-08-03 |
| Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis Zanzalintinib, Nivolumab - Locally Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Qian Qin | 69 | 2025-10-30 | 2026-09-04 |
Showing 20 of 38. Sign in to see all of them.
Carcinoma, Renal Cell (9) · Colorectal Neoplasms (5) · Carcinoma, Hepatocellular (4) · Neoplasm Metastasis (4) · Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Bone Neoplasms (2) · Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Clear-cell metastatic renal cell carcinoma (2) · Head and Neck Neoplasms (2) · Neuroendocrine Tumors (2) · Sarcoma (2) · Thyroid Carcinoma, Anaplastic (2) · Adenocarcinoma, Follicular (1)
Exelixis (13) · M.D. Anderson Cancer Center (3) · Merck Sharp & Dohme LLC (3) · Washington University School of Medicine (3) · UNC Lineberger Comprehensive Cancer Center (2) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Deepak Kilari (1) · Devalingam Mahalingam (1) · Hoffmann-La Roche (1) · Jochen Lorch (1) · Karie Runcie (1) · Kelly Fitzgerald, MD (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1)
United States (36) · France (10) · Spain (10) · United Kingdom (10) · Australia (9) · Germany (8) · Poland (8) · South Korea (8) · Italy (7) · Belgium (6) · Brazil (5) · Chile (5) · Czechia (5) · Israel (5) · Argentina (4)
Adel Kardosh (1) · Ari Rosenberg, MD (1) · David G Mutch, M.D. (1) · Deepak Kilari, MD (1) · Devalingam Mahalingam (1) · Jochen H Lorch (1) · John Livingston, MD (1) · Karie Runcie, MD (1) · Kelly Fitzgerald, MD (1) · Kimbery Perez, MD (1) · Luana Sousa, MD (1) · Mia C Weiss, M.D. (1) · Mia Weiss, M.D. (1)
PMID 39041200, PMID 40008409, PMID 40248950, PMID 41130252, PMID 42803451
P30CA060553 (3), 2017 (1), 2023 (1), 2025 (1), P30CA033572 (1), P50CA265793 (1)